Abstract
Two new copper(II) complexes [Cu(Boc–glycine)(2,2–bipyridyl)2]NO31 and [Cu(Boc–glycine)(1,10–phenanthroline)2]NO32 were prepared, and thoroughly characterized by multiple spectroscopic methods. The SC X–ray diffraction studies revealed that the complexes crystallized in triclinic (P 1¯) system with distorted square pyramidal and octahedral geometry in 1 and 2, respectively. To predict the anticancer potential of the drug candidates 1 and 2, binding studies with the ct–DNA were performed by using various complimentary biophysical methods. The drug candidates 1 and 2 interact strongly with DNA exhibiting ‘hypochromic’ effect in the absorbance bands at 300 nm implicating non–covalent intercalation binding mode that could be induced by the presence of strong recognition domain ligand (phen) which is known to ‘wedge–in’ in-between the bases of DNA helix. The intrinsic binding constant, Kb values were quantified by employing Wolfe–Shimer equation, and were found to be 0.10(±0.14) × 105 M−1 and 1.53 × 106(±0.1) M−1, respectively, showing higher binding propensity of 2 as compared to 1. pBR322 plasmid DNA cleavage studies of the complexes 1 and 2 showed that the complexes induced single–strand cleavage of DNA at a low concentration of 20 µM and 15 µM which mediated via an oxidative mechanism. The cytotoxicity activity of complexes was evaluated against MCF–7, PC–3, and HCT–116 cancer cells and the complexes displayed exceptionally good cytotoxicity against the tested cell lines (1, HCT–116:IC50 = 0.6 ± 0.02 μM and 2, MCF–7:IC50 = 1.91 ± 0.1 μM).
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call